Healthy Male Volunteers
Conditions
Keywords
Mellitus, type 2, pharmacokinetic evaluation, drug interaction between CKD-501 and metformin
Brief summary
The purpose of this study is to evaluate safety, tolerance by comparing availability and the pharmacokinetic drug interaction between the CKD-501 and metformin when administered alone and combination to healthy male volunteers.
Detailed description
Volunteers doses three times over the period of CKD-501 0.5mg and metformin 1000mg alone, repeated doses are five days. In addition, the CKD-501 0.5mg and metformin 1000mg are administered simultaneously be used repeatedly to five days. Every time before and after each medication safety and drug absorption, distribution, metabolism and excretion rate, and is expected to conduct some tests.
Interventions
DRUGMetformin
CKD-501 0.5mg, metformin 1000mg
DRUGCKD-501
CKD-501 0.5mg, metformin 1000mg
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 20 aged and 45 aged in healthy males * Weight more than 55kg, IBW 20% within the range * FPG 70\ 125 mg/dL * Agreement with written informed consent
Exclusion criteria
* Clinically significant disease(liver, heart, immune system, Respiratory system, Endocrine system, blood tumor disease, Mental illness)or a history that has learned * Test drug may affect the absorption of the gastrointestinal disease or a history that has learned * Hypersensitivity reactions to drugs or Clinically significant hypersensitivity reactions in the history of party * AST, ALT level over to 1.5 times and creatinine clearance less 80mL/min * systolic blood pressure less than 100mmHg or 150mmHg, diastolic blood pressure less than 60mmHg or greater than 95mmHg * Substance abuse, or a history of drug abuse showed a positive for the party * Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking * Previously participated in other trial within 2 months * Medication within 2 months make whole blood donation or medication within 1 month in component blood donation * Continued to be drunk or during clinical trials can not be drunk * 10 cigarettes a day for the last 3 months than the average smoker or during clinical trials can not be smoke * Containing grapefruit foods ingested during clinical trials or can not be ingested * Containing caffeine foods ingested during 24 hours before admission to hospital of can not be ingested
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CKD - 501 and metformin Pharmacokinetics evaluation | 16 days |
Secondary
| Measure | Time frame |
|---|---|
| CKD-501 and metformin safety evaluation | 16 days |
Outcome results
None listed